

1
2
3
4
5
6
7
8
9
10

Phytochemical Screening and Antimicrobial Activity of *Sarcocephalus latifolius* Smith Extracts

ABSTRACT

Aims: The aim of this work is to evaluate the antimicrobial activity of *Sarcocephalus latifolius* extracts.

Methodology: Thus, a phytochemical screening was qualitatively access using colorations or precipitations methods. Ethanolic and aqueous extracts were used to evaluate the antimicrobial activity. The antimicrobial activity, using diffusion method, was evaluated on eight strains including two reference strains (*Streptococcus pneumoniae* ATCC 49619 and *Pseudomonas aeruginosa* ATCC 27853) and six clinical isolated *S. pneumoniae* and *P. aeruginosa* strains. The minimum inhibitory concentrations (MIC) and minimum bactericidal concentrations (MBC) were determined by the microdilution method.

Results: The phytochemical screening showed the presence of flavonoids, anthocyanins, mucilages, saponosides, C-heterosides and O-heterosides. Antimicrobial activity showed that the ethanolic extract with the lowest MIC (1.25 mg/ml) inhibited reference strains (*S. pneumoniae* ATCC 49619 and *P. aeruginosa* ATCC 27853) and clinical isolated *S. pneumoniae* and *P. aeruginosa* strains. The largest inhibition diameter (19 ± 1.33) was obtained with the ethanolic extract against clinical isolated *Pseudomonas aeruginosa* and (15.5 ± 1) against the reference one. The aqueous extract inhibited only reference strains.

Conclusions: The data of this study indicate that the extracts of *S. latifolius* present antimicrobial properties. This may justify its traditional use in treatment of microbial infections.

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

Keywords: phytochemical Screening, Antimicrobial activity, *Sarcocephalus latifolius*, Benin

1. INTRODUCTION

Medicinal plants occupy an important place in African pharmacopoeia [1]. Research on medicinal plants has intensified due to the diverse therapeutic potentials that these medicinal plants possess. The evaluation of plants in traditional medicine gives us clues on how these plant parts can be used as antimicrobial agents against many pathogens [2]. The use of plant extracts and physicochemical both known for their antimicrobial properties can be of great importance in therapeutic treatments [3]. Many plants have been used because of their antimicrobial characteristics that are due to their secondary metabolites contain. *Sarcocephalus latifolius* Smith (Rubiaceae) is used in many African countries by traditional medicine practitioners for the treatment of various ailments including bacterial diseases [4].

In Africa, *S. latifolius* is widely used in traditional medicine to treat a variety disease including malaria, epilepsy and infectious diseases [4], dysentery and diarrhea [5], hernia, ascites, vomiting and colic [6]. In addition, good *in-vitro* antioxidant, anti-inflammatory and anti-diabetic effects of this plant leaf and fruit extracts have also been reported [7,8].

28 In Benin, infectious diseases are the primary public health problem [9]. These infectious
29 diseases are often caused by microbial pathogens. To control the pathogens involved in the
30 infectious diseases, antibiotic therapy is implemented currently used [10]. Unfortunately, the
31 resistance phenomenon is increasing cause of treatment failure. One of the options remains
32 to find a local and natural, such as the uses of plants, solution to mitigate these health
33 problems.

34 Among the potential plant, *S. latifolius* has been identified and used due to its medicinal
35 properties regarding gastric disorders and foodborne diseases [11]. This is proof that
36 traditional medicine still has unexplored potential. However, the main problem with traditional
37 treatments, especially those based on plants, is the lack of scientific knowledge regarding
38 efficacy, mode of action, active ingredients, doses to be administered, indications, lack of
39 properties, safety and quality control. Therefore, the present study aimed to evaluate the
40 phytochemical component and antioxidant potential of *S. latifolius* extracts.

41

42 **2. MATERIAL AND METHODS**

43

44 **2.1. Samples collection and pulverization**

45 Once collected from the surveyed area, the roots of *Sarcocephalus latifolius* were certified at
46 the National Herbarium of Benin under the identification number YH687/HNB. The collected
47 samples were then clean and dried for about 14 days in to laboratory room temperature
48 ($22\pm 2^{\circ}\text{C}$). After drying, roots samples were powdered (Retsch mill SM 2000/1430/Upm/Smf)
49 and stored until used for the different activities.

50 **2.2. Samples analysis**

51 **2.2.1. Preliminary phytochemical screening**

52 The qualitative analysis of preliminary phytochemical screening was performed directly on
53 the plant root powder using the adapted method of Houghton and Raman [12].

54 **2.2.2. Obtaining the extracts**

55 Ethanolic and aqueous extracts obtained according to a previously developed method [13]
56 were used in this study. The choice of these types of extracts is based on the way the plant
57 is traditionally used. For the aqueous extracts, 50 g of obtained powder were macerated in
58 500 ml of distilled water for 72 hours under continuous stirring. The obtained homogenate
59 was successively filtered three times on absorbent cotton and once on Whatman paper. This
60 filtrate was then dried in an oven at 50°C and the powder obtained constitutes the total
61 aqueous extract. Concerning the ethanolic, 50 g of powder was macerated in 500 ml of 96%
62 ethanol for 72 hours under continuous stirring. The mixture was then filtered three times on
63 absorbent cotton and once on Whatman n°1 to obtain a solids-free solution. The filtrate, was
64 concentrated in a rotary evaporator at 50° and stored at $2-4^{\circ}\text{C}$.

65 The extraction yield is defined as the ratio of the mass of dry extract obtained to the mass of
66 plant material processed [14]. It was obtained according to the following formula: $R (\%) =$
67 $(\text{Me}/\text{Mv}) \times 100$ with R (%): yield in %, Me: mass of dry extract, Mv: Mass of plant material
68 used.

69 **2.3. Antibacterial activity**

70 **2.3.1. Sensitivity test**

71 The *in-vitro* antibacterial activity of extracts was demonstrated by solid medium diffusion
72 method with the use of Whatman N°1 paper as previously described by Chabi Sika et al.
73 [13]. Thus, a bacterial pre-culture (1 colony in 1 mL of liquid Mueller-Hinton) from the

74 previous day is diluted to obtain a turbidity of 0.5 on the Mc Farland scale (10^8 CFU/ml) and
75 reduced to 10^6 CFU/ml in sterile distilled water. This bacterial suspension (100 μ l) is used to
76 flood a petri dish containing Mueller-Hinton agar (Bio Rad, France). The sterile discs (6 mm)
77 were deposited, under aseptic conditions, on plates previously flooded with bacterial culture.
78 On the deposited discs, 30 μ l of extract to be tested is inoculated under aseptic conditions.
79 For each extract, the experiment is duplicated and a negative control is performed with the
80 solvent instead of the extract. The plates are then left for 15-30 min at room temperature
81 before being incubated at 37°C in the oven for 24 h and 48 h. Inhibition diameters are
82 measured with a graduated ruler after incubation times of 24 h and 48 h.

83 **2.3.2. Determination of the Minimum Inhibitory Concentration (MIC)**

84 The minimum inhibitory concentrations of the extracts were determined following the
85 microdilution method using iodinitrotetrazolium (INT) as a viability indicator for bacteria [15].
86 A range of nine concentrations (10 to 0.039 mg/ml) of the extracts was tested on the
87 microbial strains. Then, 150 μ l of bacterial inoculum (10^6 CFU/ml) was added to all wells.
88 The plates were then incubated at 37°C. After 18 h of incubation, 10 μ l of INT (0.2 mg/ml)
89 was added to all wells. Plates were re-incubated at 37°C for 30 min. The MIC corresponds to
90 the first well in which no red/pink coloration due to the presence of INT is observed.

91 **2.3.3. Determination of the Minimum Bactericidal Concentration (MBC)**

92 The Minimum Bactericidal Concentration (MBC) was determined on the basis of the results
93 of the MIC determination. To do this, after identifying the MIC, we used a loop to inoculate all
94 the other wells from the MIC to the high concentrations on petri dishes containing MH agar
95 medium. Plates were examined after 24 h of incubation at 37°C. Upon observation, the
96 lowest concentration of the extract at which no bacterial growth is observed corresponds to
97 the MBC [16].

98 The antibacterial effect was considered bactericidal or bacteriostatic depending on the
99 MBC/MIC ratio [17]. Thus, the interpretation of the results is reflected in the ranges below: i-
100 $MBC/MIC \leq 4$ (bactericidal effect) and ii- $MBC/MIC > 4$ (bacteriostatic effect).

101 **2.4. Data Analysis**

102 Acquired data were analysed using GraphPad Prism 8 software. For each extract, the lethal
103 concentration that causes 50% larval death (LC_{50}) was calculated with a 95% confidence
104 interval by linear regression analysis and also using the Probit analysis method following. A
105 regression line equation, obtained from the larval mortality curve, is used to calculate the
106 concentration (LC_{50}) corresponding to the death of half the larvae.

107 **3. RESULTS AND DISCUSSION**

108 **3.1. Phytochemical screening**

109 The results of the phytochemical study of the root of *Sarcocephalus latifolius* are presented
110 in Table 1. We note a strong presence of flavonoids and an average presence of
111 anthocyanins, mucilages, saponosides, C-heterosides and O-heterosides with reduced
112 genine. On the other hand, we note the absence of catechic tannins, gall tannins,
113 leucoanthocyanins, alkaloids, reducing compounds, cyanogenic derivatives, triterpenes,
114 steroids, coumarins, quinonic derivatives, free anthracene, O-heterosides and cardiotonic
115 derivatives.

116 **Table 1.** Families of secondary metabolites sought in the root of *Sarcocephalus latifolius*


Secondary metabolites	Results
Gallic tannins	-

127 Table 4 presents the inhibitory activity of *Sarcocephalus latifolius* extracts. It appears from its
 128 analysis that the ethanolic extract has a higher inhibitory activity against the tested
 129 microorganisms than the aqueous extract. Also, the ethanolic extract shows a wide spectrum
 130 of antimicrobial activity against clinical strains. Moreover, the largest inhibition diameter was
 131 obtained with the ethanolic extract (19 ± 1.33) against *clinical Pseudomonas aeruginosa* and
 132 (15.5 ± 1) against the reference one. Thus, the inhibition diameter varies with the species.
 133 The reference strains are sensitive to the aqueous extract in 24 h but the clinical strains are
 134 resistant to this extract.

135 **Table 2.** Inhibitory activity of *Sarcocephalus latifolius* extracts against strains


Tested strains	Aqueous extract		Ethanolic extract	
	24 Hours	48 Hours	24 Hours	48 Hours
<i>S. pneumoniae</i> ATCC49619	10.5±0.5	0	12±2	9±1
<i>P. aeruginosa</i> ATCC27853	11±1	0	15.5±1	7±2
<i>Clinical isolated S. pneumoniae</i>	0	0	15±1.33	15.17±0.94
<i>Clinical isolated P. aeruginosa</i>	0	0	19±1.33	14.33±4.22

136 Figure 2 presents the sensitivity of clinical strains of *Streptococcus pneumoniae* to the
 137 extracts and reveals that within 24h and 48h, the clinical strains of *Streptococcus*
 138 *pneumoniae* are sensitive to the ethanolic extract and resistant to the aqueous extract.



139 **Figure 2.** Sensitivity of *Streptococcus pneumoniae* strains to *Sarcocephalus latifolius*
 140 extracts
 141

142 Figure 3 presents the sensitivity of clinical strains of *Pseudomonas aeruginosa* to extracts
 143 and reveals that within 24 and 48 hours, the strains of *Pseudomonas aeruginosa* are
 144 sensitive to ethanolic extract and resistant to aqueous extract.



145
 146 **Figure 3.** Sensitivity of *Pseudomonas aeruginosa* strains to *Sarcocephalus latifolius* root
 147 extracts

148 **3.3.2. Determination of the Minimum Inhibitory Concentration (MIC) and the Minimum**
 149 **Bactericidal Concentration (MBC)**

150 Table 3 presents the Minimum Inhibitory Concentration and the Minimum Bactericidal
 151 Concentration of the two extracts on the strains studied. It appears from its analysis that the
 152 aqueous extract presented MICs of 2.5 and 5 mg/ml against the reference strains while the
 153 MICs of the ethanolic extract vary from 1.25 and 2.5mg/ml. Regarding the BMC, they are
 154 10mg/ml for the aqueous extract against the reference strains and vary from 5 to 10 mg/ml
 155 for the ethanolic extract. According to the BMC/MIC ratio, we notice that all the extracts have
 156 a bactericidal effect on all the tested strains.

157 **Table 3.** Minimum Inhibitory Concentrations (MIC) and Minimum Bactericidal Concentrations
 158 (MBC) of the extracts of the three plants on the strains studied.

Strains	CMI et CMB (mg/ml) of <i>Sarcocephalus latifolius</i> extracts							
	Aqueous extract				Ethanolic extract			
	CMI	CMB	CMB/CMI	Nature of activity	CMI	CMB	CMB/CMI	Nature of activity
<i>S. pneumoniae</i> ATCC49619	5	10	2	Bactericidal	2.5	10	4	Bactericidal

<i>P. aeruginosa</i> ATCC27853	2.5	10	4	Bactericidal	2.5	10	4	Bactericidal
Clinical <i>S. pneumoniae</i>	-	-	-	/	2.5	5	2	Bactericidal
Clinical <i>P. aeruginosa</i>	-	-	-	/	1.25	5	4	Bactericidal

159 4. DISCUSSION

160 Table 1 presents the families of secondary metabolites sought in the root of *S. latifolius*.
161 From this table, it appears that the powder from the root of *S. latifolius* showed the presence
162 of secondary metabolites with the desired antimicrobial and antioxidant properties.
163 Phytochemical analysis reveals the presence of flavonoids, anthocyanins, mucilages,
164 saponosides, C-heterosides and O-heterosides with reduced genin. These secondary
165 metabolites, identified within this organ, are well known for their biological activities. The
166 results obtained are similar to those of Ahoyo et al. [9] who found alkaloids, tannins, catechic
167 tannins, gallic tannins, reducing compounds, steroids, triterpenes, quinone derivatives and
168 coumarins in the root of *S. latifolius*. This may be due to the phenology of the species and
169 also to the influence of several factors such as variation in genetic makeup, weather
170 conditions, geographical location of the plants, the part of the plant studied and the method
171 of extraction used [18, 19]. Flavonoids are recognized for their very broad and very
172 diversified antibacterial activities, very powerful antifungals, antioxidants including their
173 ability to scavenge free radicals. Also, saponosides are endowed with anti-inflammatory and
174 antibacterial activity; which justifies the antimicrobial and antioxidant power of the roots of *S.*
175 *latifolius*. Note the absence of cyanogenic derivatives and cardiotoxic glycosides, which are
176 toxic substances that would jeopardize its health safety and therefore promote its wide use
177 in traditional medicine.

178 Regarding the yield, the aqueous extract produced the highest yield (9.28%) comparing to
179 the ethanolic extract (3.54%). Similar reports were also reported by Ekong and Chijioke [20]
180 in Nigeria on extracts of *S. latifolius* where the best yield was obtained with the aqueous
181 extract (37.7%) compared to the ethanolic extract (31.0%). This could be explained by the
182 fact that several parameters affect the extraction procedure such as the chemical form of the
183 compounds studied, the extraction method, the size of the particles sampled, the parts of
184 plants used, the polarity of the solvent, the conditions drying and extraction time [21].

185 The inhibitory activity of *Sarcocephalus latifolius* extracts against strains reveals that the
186 ethanolic extract has a broad spectrum of antimicrobial activity against clinical *P. aeruginosa*
187 strains with an inhibition diameter of 19 ± 1.33 . These results are similar to those of Okwori
188 et al. [22] who in Nigeria found that the ethanolic extract produced an average inhibitory
189 zone ranging from 10 to 20 mm on *P. aeruginosa*. On the other hand, Ekong and Chijioke
190 [20] proved that the aqueous root extract of *S. latifolius* better inhibits the growth of various
191 strains where the best inhibition diameter was obtained with *P. aeruginosa* from bacteria
192 cultures. This may be due to the physicochemical extraction capacity of ethanol. Also figures
193 3 and 4 indicate to us that in 24 and 48 h, the clinical strains of *S. pneumoniae* and *P.*
194 *aeruginosa* are sensitive to the ethanolic extract and resistant to the aqueous extract in 48 h.
195 This observed resistance could be due to natural resistance, genetic variability or mutational
196 changes. The antimicrobial activity observed in the present study may be linked to the
197 richness in bioactive metabolites, in particular flavonoid and saponoside. This plant could
198 therefore be a better alternative in the effective fight against microbial infections caused by
199 *S. pneumoniae* and *P. aeruginosa*.

200 The MICs obtained vary (from 1.25 to 5mg/ml) according to the types of strains and the type
201 of extract. The lowest MIC (1.25mg/ml) was obtained with the ethanolic extract against the
202 clinical strains of *P. aeruginosa* and the highest MIC (5mg/ml) with the aqueous extract
203 against the reference strains of *S. pneumoniae*. We can therefore say that the ethanolic
204 extract has a more effective action against this strain. These results are similar to those of
205 Okwori et al. [22] who found an MIC of between 0.19 and 6.25 mg/ml with aqueous extracts

206 against strains of *Pseudomonas aeruginosa*. In addition, these results are contrary to those
207 found by Ekong and Nnatu [20] when the reported that the MIC varies between 3.13 and
208 25mg/ml and the lowest MIC (3.13mg/ml) was obtained with the aqueous extract against
209 strains of *Escherichia coli*. The differences observed between the values of our MICs and
210 those of the authors cited above could be explained by the method of extraction, the
211 solvents used and the plant organ and also the origin of the strains. Therefore, depending on
212 the extraction method, the solvent used, and even the plant organ, the antimicrobial active
213 ingredients will not have the same concentrations in the extracts.

214 Considering the CMBs, they are 10mg/ml for the aqueous extract against the reference
215 strains and vary from 5 to 10mg/ml for the ethanolic extract against the two types of strains.
216 In addition, the extracts of this plant have a bactericidal activity on all the strains studied.
217 These results corroborate those of Ekong and Nnatu [20] who showed the aqueous and
218 ethanolic extracts of the root of *Nauclea latifolius* have a bactericidal effect on the strains
219 tested. This will mean that extracts from the root of *S. latifolius* can be used as an
220 antimicrobial agent in the treatment of bacterial infections. These results clearly indicate the
221 meaning of their uses as an herbal remedy in the treatment of infectious diseases.

222 5. CONCLUSION

223 This work, with a view to confirming or invalidating the practice of medicinal plants,
224 represents a step forward in the improvement of traditional medicine in general and in
225 particular in the rational exploitation of *Sarcocephalus latifolius*. The results obtained showed
226 that the phytochemical screening revealed the presence of compounds with antioxidant and
227 antimicrobial activity. The evaluation of the antimicrobial activity showed that all the extracts
228 have a bactericidal effect on the tested strains. In view of these results, the use of the root of
229 *S. latifolius* in traditional medicine to treat pulmonary infections in general and pneumococcal
230 diseases in particular is justified. However, additional studies such as antioxidant and toxicity
231 are needed to demonstrate the efficacy and safety of *S. latifolius* root extracts.

232 233 COMPETING INTERESTS

234
235 Authors have declared that no competing interests exist.
236

237 AUTHORS' CONTRIBUTIONS

238 **K.C-S, H.S, B.B, I.M-S and L.B-M** designed the study, performed the statistical analysis,
239 wrote the protocol, and wrote the first draft of the manuscript. **G.R. A.K, L.K, H.A.S, S.A.A**
240 **and M.Y.A** managed the analyses of the study. **'K.C-S, I.M-S, B.B, L.K, and H.S** managed
241 the literature searches. All authors read and approved the final manuscript.
242

243 REFERENCES

- 244
245 1. Badiaga, M. Etude ethnobotanique, phytochimique et activités biologiques de
246 *Nauclea latifolia Smith*, une plante médicinale africaine récoltée au Mali. Thèse de
247 doctorat en chimie organique, Faculté des Sciences et Techniques, Université de
248 Bamako, 2011, pp 137.
249 2. Farombi, E.O. African indigenous plants with chemotherapeutic potential and
250 biotechnological approach to the production of bioactive prophylactic agent. *Afr. J.*
251 *Biotechnol*, 2003, 2(2) : 662-671.
252 3. Seenivasan, P., Manickam, J., Savarimuthu, I. *In vitro* antibacterial activity of some
253 plant essential oils. *BMC Complem. Altern. Med.*, 2006, 6 : 39. doi:10.1186/1472-
254 6882-6-39.

- 255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
4. Boucherle B., Haudecoeur, R., Queiroz, E. F., De Waard, M., Wolfender, J.L., Robins, R. J., Boumendjel, A. *Nauclea latifolia*: biological activity and alkaloid phytochemistry of a West African tree. *Nat. Prod. Rep*, 2016, 33(9), 1034-1043.
 5. Okwu, D.E., Uchenna, N.F. Exotic multifaceted edicinal plants of drugs and pharmaceutical industries. *Afr. J. Biotechn.* 2009, 8(25), 7271-7282.
 6. Adjanohoun, E. Contribution aux études ethnobotaniques et floristiques en République Populaire du Bénin. Agence de Coopération Technique et Culturelle, Paris. 1989, 1. 895 p.
 7. Iheagwam, F. N., Nsedu, E. I., Kazeem, O. K , Opeyemi C. D.C., Olubanke O. O. and S. C., Nwodo, 2020. *Nauclea latifolia* Sm. Leaf Extracts Extenuates Free Radicals, Inflammation, and Diabetes-Linked Enzymes, *Oxidative Medicine and Cellular Longevity* (2020), pp 13.
 8. Ademola O. A., Oluwafèmi O. O., Brooks, N. L. *In vitro* study on the antioxydant potentials of leaves and fruits of *Nauclea latifolia*. *The Sci World. J.* 2014, pp 8.
 9. Ahojo, C.C., Deguenon, P.M., Dah-Nouvlessounon, D., Sina, H., Houehanou, D.T., Yaoitcha, A.S., Baba-Moussa, L.; Houinato, M.R.B. Comparative *in vitro* antimicrobial effect of *Sarcocephalus latifolius* (Sm.) E. A. Bruce leaves and roots on foodborne pathogens. *Afr. J. Microbiol. Res.* 2019, 13 (22) 357-368.
 10. Bush L. M.; Vazquez-Pertejo, M T. Infections à pneumocoques. LE MANUEL. 2021. Available online : <https://www.msmanuals.com/fr/professional/maladies-infectieuses/cocci-gram-positifs/infections-streptococciques>
 11. Kaboré, S.A., Hien, M., Ouédraogo, D., Diallo, T.R.E., Hahn, K., Nacro, H.B. Use of ecosystem services of *Sarcocephalus latifolius* (Sm.) E. A. Bruce and induced effect of human pressure on the species in the southwestern region of Burkina Faso. *Ethnobot. Res. Appl.* 2014, 12:561-570.
 12. Houghton, P.J.; Raman, A. Laboratory Handbook for fractionation of natural extracts. Pharma. Res. Lab, Departement of Pharmacy, king's college, London, 1998, pp 212.
 13. Chabi-Sika K.; Sina H.; Bawa B.; Bade F.; Hounnou, T.; Badoussi, M.E.; Adjatin, A., L.; Baba-Moussa. *Richardia brasiliensis* Collected in Southern-Benin: Phytochemical Screening, Antimicrobial Activity and Toxicity. *Asi. J. Biol*, 2021, 13 (4): 22-33.
 14. Harborne, J.B. Phytochemical Methods: A guide to modern techniques of plant analysis. *Chapman & Hall*, 1998, 3:202-209.
 15. Amoussa A.M.O.; Sanni A.; Lagnika, L. Antioxidant activity and the estimation of total phenolic, flavonoid and flavonol contents of the bark extracts of *Acacia ataxacantha*. *J. Pharm. Phytochem*, 2015, 4(2) : 172-178.
 16. Moroh, J.L.A., Bahi, C., Dje, K., Loukou, Y.G., Guede-Guina, F. Étude de l'activité antibactérienne de l'extrait acétatique (EAC) de *Morinda morindoides* (Baker) milne-redheat (Rubiaceae) sur la croissance *in-vitro* des souches d'*Escherichia coli*. *Bull de la Soc Roy des Sci de Liège*, 2008, 77: 44-61.
 17. Kamanzi, A.K., Plantes médicinales de Côte d'Ivoire: Investigations phytochimiques guidées par des essais biologiques. Thèse de doctorat, Université de Cocody, Abidjan, 2002, 176p.
 18. Sujana, P., Sridhar, T.M., Josthna, P., Naidu, C.V. Antibacterial activity and phytochemical analysis of *Mentha piperita* L. (Peppermint) an important multipurpose medicinal plant. *Am. J. Plant Sci.* 2013, 4, 77-83.
 19. Akhtar N., Ihsan-ul-Haq, Mirza, B. Phytochemical analysis and comprehensive evaluation of antimicrobial and antioxidant properties of 61 medicinal plant species. *Arab. Rev. Chem*, 2018, 11(2), 1223-1235.
 20. Ekong, U. S., Nnatu, C. M. Phytochemical composition and *in vitro* antimicrobial activities of *Nauclea latifolia* root extracts. *Sky J. Microbiol. Res.* 2016, 4 (3), 008 - 014.

- 308 21. Dah-Nouvlessounon, D.; Adoukonou-Sagbadja, H.; Diarrassouba, N.; Sina H.;
309 Adjonohoun, A.; Inoussa, M.; Akakpo, D.; Gbenou, J.D.; Kotchoni, S.O.; Dicko,
310 M.H.; Baba-Moussa, L. Phytochemical analysis and biological activities of *Cola*
311 *nitida* bark. *Biochem. Res. Int.* 2015, 1-12.
- 312 22. Okwori, A. E.J.; Okeke, C.I.; Uzochina, A.; Etukudoh, N.S.; Amali, M.N.; Adetunji,
313 J.A.; Olabode, A.O. The antibacterial potentials of *Nauclea latifolia*. *Afr. J. Biotech.*,
314 2008. 7(10), 1394-1399.
315
316